Statistics for Pembrolizumab alone or in combination with chemotherapy as first-line therapy for patients with advanced gastric or gastroesophageal junction adenocarcinoma: results from the phase II nonrandomized KEYNOTE-059 study
Total visits
| views | |
|---|---|
| Pembrolizumab alone or in combination with chemotherapy as first-line therapy for patients with advanced gastric or gastroesophageal junction adenocarcinoma: results from the phase II nonrandomized KEYNOTE-059 study | 187 |
Total visits per month
| views | |
|---|---|
| November 2024 | 0 |
| December 2024 | 0 |
| January 2025 | 0 |
| February 2025 | 0 |
| March 2025 | 0 |
| April 2025 | 0 |
| May 2025 | 0 |
File Visits
| views | |
|---|---|
| 10120_2018_Article_909.pdf | 281 |
| java.util.UUID:1773e9cb-322e-4d80-86db-2739bbb7d4f6 | 44 |
| java.util.UUID:f12a013e-c622-4e0e-a7c2-2c2af1b2e82a | 20 |
| java.util.UUID:302d4cc2-302a-464b-aa8c-20e2ff5af01a | 6 |
Top country views
| views | |
|---|---|
| United States | 129 |
| Germany | 21 |
| Ukraine | 4 |
| China | 3 |
| United Kingdom | 3 |
| Canada | 2 |
| Chile | 2 |
| India | 1 |
| Malaysia | 1 |
| Portugal | 1 |
| Russia | 1 |
| Sweden | 1 |
Top city views
| views | |
|---|---|
| Wilmington | 51 |
| Fairfield | 20 |
| Houston | 13 |
| Kiez | 10 |
| Gunzenhausen | 9 |
| Cambridge | 5 |
| Jacksonville | 5 |
| Kiev | 4 |
| Ann Arbor | 3 |
| Dearborn | 3 |
| Nürnberg | 2 |
| San Francisco | 2 |
| Toronto | 2 |
| Baltimore | 1 |
| Brooklyn | 1 |
| Duncan | 1 |
| Huaian | 1 |
| Indianapolis | 1 |
| Kansas City | 1 |
| Linda-a-velha | 1 |
| Moscow | 1 |
| Mumbai | 1 |
| Quzhou | 1 |
| Scottsdale | 1 |
| Seremban | 1 |
| Stockholm | 1 |
| Washington | 1 |